Literature DB >> 29182448

Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy.

Serena Bonin1, Nunzia Zanotta2, Arianna Sartori3, Alessio Bratina3, Paolo Manganotti1,3, Giusto Trevisan1,3, Manola Comar1,2.   

Abstract

BACKGROUND: Cerebrospinal fluid (CSF) analysis in patients with particular neurologic disorders is a powerful tool to evaluate specific central nervous system inflammatory markers for diagnostic needs, because CSF represents the specific immune micro-environment to the central nervous system.
METHODS: CSF samples from 49 patients with multiple sclerosis (MS), chronic inflammatory demyelinating polyneuropathy (CIDP), and non-inflammatory neurologic disorders (NIND) as controls were submitted to protein expression profiles of 47 inflammatory biomarkers by multiplex Luminex bead assay to investigate possible differences in the inflammatory process for MS and CIDP.
RESULTS: Our results showed differences in CSF cytokine levels in MS and CIDP; in particular, IL12 (p40) was significantly highly expressed in MS in comparison with CIDP and NIND, while SDF-1α and SCGF-β were significantly highly expressed in CIDP cohort when compared to MS and NIND. IL-9, IL-13, and IL-17 had higher expression levels in NIND if compared with the other groups.
CONCLUSIONS: Our study showed that, despite some common pathogenic mechanisms, central and peripheral nervous system demyelinating diseases, such as MS and CIDP, differ in some specific inflammatory soluble proteins in CSF, underlining differences in the immune response involved in those autoimmune diseases.

Entities:  

Keywords:  Multiple sclerosis; central and peripheral nervous system; cerebrospinal fluid; chronic inflammatory demyelinating polyneuropathy; inflammatory biomarkers

Mesh:

Substances:

Year:  2017        PMID: 29182448     DOI: 10.1080/08820139.2017.1405978

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  6 in total

1.  Cerebrospinal Fluid in Classical Trigeminal Neuralgia: An Exploratory Study on Candidate Biomarkers.

Authors:  Teodor Svedung Wettervik; Dick Folkvaljon; Torsten Gordh; Eva Freyhult; Kim Kultima; Hans Ericson; Sami Abu Hamdeh
Journal:  Biomedicines       Date:  2022-04-26

2.  Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies.

Authors:  Michael Heming; Andreas Schulte-Mecklenbeck; Tobias Brix; Jolien Wolbert; Tillmann Ruland; Luisa Klotz; Sven G Meuth; Catharina C Gross; Heinz Wiendl; Gerd Meyer Zu Hörste
Journal:  Front Immunol       Date:  2019-03-21       Impact factor: 7.561

3.  Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients.

Authors:  Zhile Bai; Duanduan Chen; Luyao Wang; Yu Zhao; Tiantian Liu; Yun Yu; Tianyi Yan; Yong Cheng
Journal:  Front Neurosci       Date:  2019-10-04       Impact factor: 4.677

4.  Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups.

Authors:  Gloria Donninelli; Valeria Studer; Laura Brambilla; Chiara Zecca; Daniele Peluso; Alice Laroni; Daniele Michelis; Renato Mantegazza; Paolo Confalonieri; Elisabetta Volpe
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

5.  Progress in brain barriers and brain fluid research in 2017.

Authors:  Richard F Keep; Hazel C Jones; Lester R Drewes
Journal:  Fluids Barriers CNS       Date:  2018-02-02

6.  Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy.

Authors:  Petra Huehnchen; Wolfgang Boehmerle; Matthias Endres
Journal:  Sci Rep       Date:  2018-04-04       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.